Myriad Genetics (MYGN) Announces Thomas P. Slavin, M.D., Named Chief Medical Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics
June 16, 2021 4:05 PM EDTSALT LAKE CITY, June 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has named Thomas P. Slavin Jr. (T.J.), M.D., FACMG, DABMD, chief medical officer of the company. He will report directly to Nicole Lambert, president of Myriad Genetic Laboratories.
In his new role, Dr. Slavin will apply deep clinical and scientific expertise, combined with proven leadership and experience in precision medicine, to further elevate Myriads portfolio of genetic tests spanning oncology, womens health and... More
